China SXT Pharmaceuticals Return on Equity

China SXT Pharmaceuticals (SXTC) currently reports a ROE of -24.82%. That is below the Consumer Discretionary sector average of 21.77%. Use the charts on this page to explore China SXT Pharmaceuticals's ROE history and peer comparisons.

China SXT Pharmaceuticals's ROE of -24.82% is lower than the Consumer Discretionary sector average of 21.77%. That is roughly 214.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but China SXT Pharmaceuticals's current -24.82% should be judged against Consumer Discretionary norms (sector average: 21.77%) and against SXTC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -24.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 21.77%. From there, open related valuation or income-statement pages for China SXT Pharmaceuticals, and consider following SXTC for alerts when major investors trade the stock.

China SXT Pharmaceuticals is classified in the Consumer Discretionary sector. On ROE, it currently shows -24.82% versus a sector average near 21.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing SXTC with unrelated industries.